Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 17Other solid neoplasm 17Gastrointestinal 6Gynecologic 5Genitourinary 5Head & Neck 4Dermatologic 4Breast 4Endocrine 2Sarcoma 1NET 1CNS 1

Conditions

Neuroendocrine Tumors 12Carcinoma, Neuroendocrine 8Carcinoma, Non-Small-Cell Lung 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma 2Pheochromocytoma 2Penile Neoplasms 2Parathyroid Neoplasms 2Paraganglioma 2Ovarian Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Mesothelioma 2Melanoma 2Hemangiosarcoma 2Gastro-enteropancreatic neuroendocrine tumor 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Adenoid Cystic 2Adrenal Gland Neoplasms 2

Interventions

Nivolumab 2pembrolizumab 1olaparib 1fludarabine phosphate 1fludarabine 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Molecular Diagnostic Techniques 1LY2940680 1Irinotecan 1Immunotherapy 1IPI-549 1Fluorodeoxyglucose F18 1Drug Therapy 1Cyclophosphamide 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma × Nivolumab × Endocrine × Clear all
NCT06638931 2026-04-15

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
28 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Infinity Pharmaceuticals, Inc.

Phase 1 Unknown
219 enrolled
BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡